Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Bayer heralds pipeline progress, blockbuster launches and advanced flagship products in cell-gene therapy: Our Bureau, Bengaluru Wednesday, April 2, 2025, 14:50 Hrs [IST] Bayer Ph ...

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...

Q4 2024 Earnings Call Transcript March 31, 2025 Brainstorm Cell Therapeutics Inc. reports earnings inline with expectations.

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year ...

Chaim Lebovits; President, Chief Executive Officer; Brainstorm Cell Therapeutics Inc. Alla Patlis; Interim Chief ...

From stock decline to Hold rating, explore their growth strategy, client focus, and potential gains. Click for my MRVI update ...

Health plans often limit physical therapy to 20 or 30 sessions, even for people who may need months of treatment, multiple ...

Family courts harm children when they base decisions on the questionable concepts of parental alienation and reunification ...